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Therapeutic effects of prostacyclin analog on crescentic glomerulone-
phritis of rat. Prostacyclin (PGI2) is known to have a relaxative action on
vascular smooth muscle, an inhibitory action against platelet activation
and neutrophil function. Previous studies showed the preventive effects of
PGI2 on lupus nephritis and Thy-1 nephritis, although the mechanism has
not been clarified. Glomerular endothelial expression of intercellular
adhesion molecule-1 (ICAM-1) is up-regulated in experimental and
human glomerular diseases, and is known to facilitate leukocyte infiltra-
tion into the glomeruli, which ultimately induces the various glomerular
injuries. In the present study, we evaluated the therapeutic effects of PGI2
on a rat model for crescentic glomerulonephritis and investigated its
putative mechanism in relation to ICAM-1-mediated leukocyte recruit-
ment. Wistar-Kyoto (WKY) rats were injected with nephrotoxic serum
and received continuous intraperitoneal infusion of PGI2. PGI2 dramati-
cally decreased proteinuria (123.0 6 18.8 vs. 31.6 6 4.5), crescent
formation and deposition of fibrinogen in the glomeruli, while the
deposition of rabbit IgG, rat IgG and rat C3 along the capillary walls was
not changed. Furthermore, intraglomerular expression of ICAM-1 and
infiltration of macrophages were significantly suppressed by administra-
tion with PGI2. In contrast, influx of CD4 or CD8 positive cells was not
altered. The present results suggest that PGI2 shows the preventive effects
on experimental crescentic glomerulonephritis by inhibiting intraglomeru-
lar coagulation and ICAM-1-mediated macrophage-glomerular endothe-
lial cell adhesive pathway.
Prostacyclin (PGI2) is known to have a relaxative action on
vascular smooth muscle [1], an inhibitory action against platelet
aggregation [2, 3] and neutrophil function [4, 5]. Recently, it has
been reported that PGI2 ameliorated anti-Thy-1 glomerulone-
phritis and the nephritis in NZB/W F1 mice, which spontaneously
develop a kidney disease similar to systemic lupus erythematosus
in humans [6–8], although the mechanism has not been clarified.
Intercellular adhesion molecule-1 (ICAM-1) is known to play a
key role for leukocyte infiltration into the glomeruli in various
types experimental models of renal diseases. Among these exper-
imental models, the Wistar-Kyoto (WKY) rat is known to develop
crescentic glomerulonephritis after injection with anti-glomerular
basement membrane (GBM) antibody [9], and the expression and
role of ICAM-1 has been well studied. Kawasaki et al reported
that, in this model, ICAM-1 promotes intraglomerular infiltration
of macrophages that are involved in crescent formation, and that
anti-ICAM-1 antibody prevent macrophage infiltration and cres-
cent formation [9].
Since ICAM-1 is up-regulated by various cytokines and PGI2 is
negative regulator of these cytokines, we evaluated the effects of
PGI2 on the expression of ICAM-1 in the glomeruli and also renal
tissue injuries using a WKY rat model for crescentic glomerulo-
nephritis.
METHODS
Preparation of nephrotoxic serum
Normal Wistar rat kidneys were fully perfused with physiologic
saline through a catheter placed in the aorta. Renal cortical tissue
was removed, homogenized and diluted with physiologic saline at
about 20% suspension. Two milliliters of renal cortical homoge-
nate were emulsified with an equal volume of Freund’s complete
adjuvant (Difco Laboratories, Detroit, MI, USA). This emulsion
was injected subcutaneously into rabbits twice a month for two
months. Seven days after the last injection, the rabbits were bled
from the carotid artery under anesthesia. The sera were de-
complemented for 30 minutes at 56°C and absorbed with freshly
harvested rat erythrocytes. Preliminary immunohistochemical ex-
periments showed that the intravenous injection of 1.0 ml of NTS
into Wistar rats, which weighted about 100 g, resulted in linear
binding of rabbit IgG along the GBM.
Agents
The stable PGI2 analog, beraprost (sodium-2,3,3a,8b-
tetrahydro-2-hydroxy-1-[(E)-(3S)-3-hydroxy-4-methyl-1-octen-6-
ynyl]-1H-cyclopenta[b]benzofuran-5-butyrate) was provided by
Toray Industries, Inc. (Tokyo, Japan) [10].
Antibodies
Mouse monoclonal antibodies against rat monocytes/macro-
phages (ED-1), rat CD4, and rat CD8 were purchased from
Serotec Ltd. (Kidlington, Oxford, UK). Preparation and charac-
terization of mouse monoclonal antibody against rat ICAM-1
(1A29) have previously been described [11]. Fluorescein isothio-
cyanate (FITC)-labeled and biotin-labeled donkey anti-mouse
IgG antibodies were purchased from Jackson Immunoresearch
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Laboratories (West Grove, PA, USA). FITC-labeled goat anti-rat
IgG, goat anti-rat C3, goat anti-rat fibrinogen and goat anti-rabbit
IgG antibodies were purchased from Cappel (Costa Mesa, CA,
USA).
Experimental protocol
Ten male WKY rats (150 g) were obtained from Charles River
Japan (Atsugi, Kanagawa, Japan). All rats were fed on standard
chow and water ad libitum. Ten WKY rats were randomly devided
into two groups of five rats. One group received continuous
intraperitoneal administration of 30 mg/rat/day of beraprost by an
osmotic pump (ALZA Co., Palo Alto, CA, USA). Another
control group received administration of physiological saline
instead of beraprost. Twenty-four hours after starting administra-
tion, both groups of rat were injected with 1.0 ml of NTS
intravenously, which induced glomerulonephritis. At 9, 12, 14
days, urine samples were collected and urinary protein levels were
measured by using the Lowry method. At 14 days the rats were
sacrificed under ether anesthesia, and both kidneys were removed.
Portions of these tissues were processed for light microscopy,
immunofluorescence staining and immunoperoxidase staining.
Systemic blood pressure was measured by tail-cuff plethysmogra-
phy (UR-5,000; Ueda Seisakusyo, Tokyo, Japan).
Light microscopy
Tissues were fixed in 10% formalin and embedded in paraffin.
Paraffin sections (4 mm) were then stained with hematoxylin and
eosin, and periodic acid-Sciff. Twenty glomeruli were examined
per rat, and number of glomeruli which forms crescent was
counted.
Immunofluorescence staining
Indirect immunofluorescence studies were performed on 3
mm-thick cryostat sections as described previously [12]. In brief,
sections were air dried and incubated with anti-rat ICAM-1
antibody for 60 minutes at room temperature. After washing with
PBS, antibody binding was visualized by incubating the sections
for 30 minutes with FITC-labeled goat anti-mouse IgG.
Direct immunofluorescence studies were performed on 4 mm-
thick cryostat sections, which were incubated with FITC-labeled
goat anti-rat IgG, goat anti-rat C3, goat anti-rat fibrinogen and
goat anti-rabbit IgG.
The staining intensity was semiquantitatively graded according
to following scale: 0 5 no staining; 1 5 weak staining; 11 5
moderate staining; 111 5 strong staining. Twenty glomeruli
were examined per rat by two observers without knowledge of
whether the section was from the beraprost group or control
group.
Immunoperoxidase staining
The distribution of leukocyte was examined by using the
immunoperoxidase ABC kit (Vector Lab., Burlingame, CA, USA)
as described previously [13]. In brief, nonspecific protein binding
was blocked by incubating the cryostat sections with 10% bovine
serum in Tris-buffered saline for 20 minutes. Nonspecific staining
was blocked by a 15 minute incubation with avidin and then biotin
using the avidin-biotin blocking kit (Vector Lab.). Endogenous
peroxidase activity was inhibited by incubating the sections in
methanol containing 0.3% H2O2 for 20 minutes.
Sections were first incubated for 60 minutes with primary
antibodies at room temperature, incubating monoclonal antibod-
ies against rat monocytes/macrophages (ED-1), rat CD4 and rat
CD8. Then sections were incubated with biotinylated donkey
anti-mouse IgG for 30 minutes at room temperature. Biotinylated
horseradish peroxidase was applied for 30 minutes at room
temperature. Peroxidase activity was developed in 3,3-diamino-
benzidine and hydrogen peroxide. The sections were then coun-
terstained with Mayer’s hematoxylin.
The number of ED-1 positive cells, CD4 positive cells and CD8
positive cells per glomerular cross-section was counted by two
observers without knowledge of whether the section was from the
beraprost group or control group. Twenty glomeruli were exam-
ined per rat, and the average number of positive cell per glomer-
ulus was calculated.
Statistical analysis
Significance of differences between groups was determined
utilizing the Wilcoxon’s test. P values of less than 0.05 were
considered significant. All data are expressed as means 6 SEM.
RESULTS
Metabolic data
Beraprost-treated rats had significantly lower urinary protein
excretion than saline-treated control rats from 12 days after
induction of glomerulonephritis (Fig. 1) (24.7 6 6.3 mg/day vs.
8.4 6 0.4 mg/day at 12 days, 123.0 6 18.8 mg/day vs. 31.6 6 4.5
mg/day at 14 days). In contrast, no differences in systemic blood
pressure, platelet counts (149.4 6 9.8 3 104/mm3 vs. 126.0 6 9.6 3
104/mm3), leukocyte counts (7160 6 923/mm3 vs. 6600 6 822/
mm3), serum creatinine levels (0.4 6 0.04 mg/dl vs. 0.4 6 0.04
mg/dl), creatinine clearances (1.88 6 0.27l/day vs. 1.77 6 0.19l/
day), serum total protein levels (5.4 6 0.5g/dl vs. 5.4 6 0.4 g/dl) or
plasma fibrinogen levels (108 6 36 mg/dl vs. 101 6 34 mg/dl) were
noted in beraprost-treated and control rats.
Renal histopathology
By light microscopy, the glomeruli in the control rats showed a
severe mesangial hypercellularity, mesangial matrix expansion,
Fig. 1. Effect of beraprost on urinary protein excretion of experimental
crescentic glomerulonephritis. Beraprost-treated rats (n) have signifi-
cantly lower urinary protein excretion than saline-treated control rats (h)
from 12 days after induction of glomerulonephritis. **P , 0.01, *P , 0.05.
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necrotizing lesions and cellular crescent formation (Fig. 2A). On
the other hand, those in beraprost-treated rats showed little or no
alteration (Fig. 2B). In the beraprost-treated rat kidneys, only
10% of the glomeruli showed crescentic formation, although 80%
of the glomeruli in control rats were crescentic. In both groups,
the influx of leukocytes in the interstitium was restricted.
In the immunofluorescence study, both the control and bera-
prost-treated groups exhibited a similar fluorescence intensity of
rabbit IgG, rat IgG and rat C3 along the capillary walls in a linear
pattern. Thus, the binding of rabbit anti-rat GBM antibody and
complement activation were not altered by treatment of PGI2.
Fibrinogen was intensely stained in the capillary and mesangial
areas in the glomeruli of the control rats, and also the cellular
crescents showed an intense immunoreactivity of fibrinogen (Fig.
3A). In beraprost-treated rats, the staining intensities of rat
fibrinogen were significantly lower than those in control rats (Fig.
3B). The scored immunofluorescent intensity of fibrinogen in
each group is indicated in Fig. 6 (1.65 6 0.3 vs. 2.25 6 0.3).
Expression of ICAM-1 in the glomeruli
The ICAM-1 positive cells were endothelial cells of large
vessels and peritubular capillaries in the normal kidney. There was
little or no expression of ICAM-1 in the normal glomeruli. By the
indirect immunofluorescence study, the NTS-treated control
group exhibited ICAM-1 expression intensely along the capillary
wall and somewhat mesangial areas in addition to peritubular
capillaries (Fig. 4A). In beraprost-treated rats, ICAM-1 was
expressed faintly in segmental capillary wall (Fig. 4B). Semiquan-
tification of immunofluorescent intensity of ICAM-1 in each
group is indicated in Fig. 6 (2.05 6 0.3 vs. 2.55 6 0.3).
Immunohistochemical analysis of intraglomerular leukocytes
By the immunoperoxidase study, the control group exhibited a
massive influx of macrophages into the glomeruli (64.7 6 2.8/
glomerulus). In contrast, in the beraprost-treated group, infiltra-
tion of macrophages was significantly prevented (31.6 6 1.6/
glomerulus, Figs. 5 and 6). The number of CD4 positive cells
(4.2 6 0.3/glomerulus vs. 4.2 6 0.3/glomerulus) and CD8 positive
cells (4.5 6 0.3/glomerulus vs. 4.3 6 0.2/glomerulus) were not
changed between the control and beraprost-treated groups.
DISCUSSION
WKY rats are known to be more susceptible to anti-GBM
antibody than other strains, and develop progressive proteinuria
and crescentic glomerulonephritis [9]. Kawasaki et al reported
that this model induced the up-regulation of ICAM-1 in the
glomeruli and high influx of leukocytes mainly composed of
macrophages and CD8-positive T lymphocytes [9]. They reported
that macrophage plays a central role in the progression of
crescentic glomerulonephritis and that anti-ICAM-1 monoclonal
Fig. 2. Light microscopic appearance of control (A) and beraprost-treated (B) groups at 14 days after injection of nephrotoxic serum. In the kidney
of beraprost-treated rats, only 10% of glomeruli shows crescentic formation, although 80% of glomeruli shows crescentic formation in control rats
(hematoxylin and eosin; 3200).
Kushiro et al: Attenuation of glomerulonephritis by prostacyclin1316
Fig. 3. Immunofluorescence micrographs of glomeruli from control (A) and beraprost-treated (B) groups at 14 days after injection of nephrotoxic
serum stained with antibody against rat fibrinogen. Fibrinogen is intensely stained in the capillary, mesangial areas and cellular crescent in the glomeruli
of the control rats. In beraprost-treated rats, the staining intensities of rat fibrinogen are significantly lower than those in control rats (3200).
Fig. 4. Immunofluorescence micrographs of glomeruli from control (A) and beraprost-treated (B) groups at 14 days after injection of nephrotoxic
serum stained with antibody against rat ICAM-1. The control group exhibits ICAM-1 expression intensely along the capillary wall. In the
beraprost-treated rats, ICAM-1 is expressed faintly in segmental capillary wall (3200).
antibody reduced the infiltration of macrophages and crescent
formation.
Our present study demonstrated that the stable PGI2 analog,
beraprost, largely suppressed the development of the experimen-
tal crescentic glomerulonephritis in rats. Beraprost reduced glo-
merular expression of ICAM-1 and infiltration of macrophages,
and prevented glomerular crescent formation and proteinuria.
The adhesive interaction between leukocytes and endothelium
Fig. 5. Immunoperoxidase micrographs of glomeruli from control (A) and beraprost-treated (B) groups at 14 days after injection of nephrotoxic serum
stained with antibody against rat monocytes/macrophages. The control group exhibits a massive influx of macrophages into the glomeruli. In contrast,
in beraprost-treated group, infiltration of macrophages is significantly prevented (3400).
Fig. 6. Glomerular staining scores of fibrinogen (A) and ICAM-1 (B), and the number of monocytes/macrophages (C) of experimental crescentic
glomerulonephritis. Symbols are: (h) control group; (n) beraprost-treated group; *P , 0.01, **P , 0.05.
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is very important in the early phase of inflammation. While
leukocytes are only minimally adherent to endothelium under
normal circumstance, stimulation with cytokines enhances their
adhesiveness to endothelial cells. This enhanced adhesion is
dependent on cell adhesion molecules expressed on the endothe-
lial cells such as ICAM-1. Kawasaki et al [9] and Nishikawa et al
[14] reported that anti-ICAM-1 monoclonal antibody prevented
influx of monocytes (ED-1 positive cells) into the glomeruli in rat
experimental crescentic glomerulonephritis. Mulligan et al re-
ported that anti-ICAM-1 antibody showed preventive effect on
neutrophil infiltration into the glomeruli in anti-GBM antibody-
induced glomerular injury [15]. We also showed the preventive
effect of anti-ICAM-1 antibody on intraglomerular influx of
neutrophil and macrophage in Masugi nephritis [16].
In this study, we speculate that two mechanisms of PGI2
showed the preventive effects on proteinuria and crescent forma-
tion. Firstly, beraprost diminished ICAM-1 expression and infil-
tration of macrophages in the glomeruli of this model, suggesting
that beraprost prevented the infiltration of macrophages by
inhibiting the expression of ICAM-1. The direct effect of bera-
prost on the expression of ICAM-1 on vascular endothelium has
not been known. However, the expression of ICAM-1 is well
known to be induced by inflammatory cytokines [17]. PGI2 and
PGE1 can inhibit the activation of platelets and release of
inflammatory mediators derived from platelets and leukocytes,
including neutrophils and macrophages [18–20]. Therefore, PGI2
may inhibit glomerular expression of ICAM-1 by preventing the
release of inflammatory cytokines. Another possible mechanism is
the alteration of hemodynamics in the glomeruli. It has been
demonstrated that shear stress induced the expression of ICAM-1
on vascular endothelial cells [21]. Beraprost has a relaxative effect
on vascular smooth muscle cells. One of the mechanisms may be
that beraprost altered the hemodynamics of microcirculation in
the glomeruli, although systemic blood pressure and creatinine
clearance were not changed after beraprost treatment in our
study.
Secondarily, one can speculated that the continuous infusion of
beraprost altered the “immunocompetence” of macrophages,
including their ability to elaborate cytotoxic cytokines, reactive
oxygen radicals, as well as their ability to respond to chemotactic
stimuli such as intraglomerular activation of complement.
Thirdly, beraprost significantly diminished fibrin deposition in
the glomeruli of this model, indicating that beraprost inhibited
intraglomerular coagulation. Several authors reported that PGI2
possesses an inhibitory action on platelet aggregation [2, 3].
Ameliorated intraglomerular coagulation by PGI2 perhaps was
related to this action. In addition, Kato et al and Grosser et al
reported that PGI2 is negative regulator of platelet-derived
growth factor (PDGF) [22, 23]. PDGF is known to be one of the
important factor to progress glomerulonephritis [24]. Down-
regulation of PDGF by PGI2 may prevent the progression of
glomerulonephritis of this model.
In our experiment, the binding of rabbit IgG to GBM and
deposition of C3 in the glomeruli were not changed by adminis-
tration with beraprost. These findings shows that beraprost did
not affect the binding of NTS to GBM and complement activa-
tion. It is reported that PGI2 participates in regulation of T cell
function primed by antigen [25, 26]. However, the deposition of
rat IgG on GBM was not changed by treatment with beraprost,
suggesting that beraprost did not affect the antibody production
against rabbit immunoglobulin.
In conclusion, our results suggest that the PGI2 analog, bera-
prost, ameliorates crescentic glomerulonephritis by reducing glo-
merular expression of ICAM-1 and intraglomerular coagulation.
This agent may be useful for the therapy of human crescentic
glomerulonephritis.
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